Cizzle Bio Welcomes Dr. Mark Miglarese as Senior Lab Advisor
Cizzle Bio, Inc. is pleased to announce that Mark Miglarese, Ph.D., has joined our team as Senior Lab Advisor.
Dr. Miglarese brings more than 30 years of scientific and operational leadership across oncology research and development, translational and clinical research, diagnostics, laboratory science, and precision medicine. His extensive career includes senior executive roles in both biopharma and diagnostics, with a proven record of advancing novel therapeutics and cutting-edge diagnostics into clinical practice.
He is the founder of Oncobellum LLC, a consulting firm specializing in precision oncology therapeutics and diagnostics. Most recently, he served as Senior Vice President (SVP) of Correlative Science at Caris Life Sciences, where he oversaw data science initiatives, including the development and validation of predictive and prognostic algorithms using advanced machine learning and AI platforms. Earlier at Caris, he held leadership roles as SVP of Drug Discovery and SVP of Clinical Laboratories, where he directed tissue and liquid biopsy labs, Regulatory Affairs, and Translational Sciences. Under his leadership, Caris achieved extraordinary growth, including a 464% increase in tissue case volume over five years while maintaining industry-leading turnaround times.
His career also includes serving as CSO of GeneCentric, VP of Oncology Translational and Clinical Science at OSI/Astellas, Head of Translational Research at Array BioPharma, and Section Head in the Department of Cancer Research at Bayer. He has also advised innovative oncology start-ups, including serving as interim CSO for Cielo Therapeutics.
Dr. Miglarese’s contributions have been integral to multiple FDA approvals, including MEKTOVI® (binimetinib), KOSELUGO® (selumetinib), FOTIVDA® (tivozanib), STIVARGA® (regorafenib), and TUKYSA® (tucatinib), as well as the PMA approval of MI Cancer Seek, the first consolidated whole exome/whole transcriptome assay approved by the FDA.
He earned his B.S. in Biology from Virginia Tech, his Ph.D. in Microbiology and Immunology from the University of Virginia, and completed post-doctoral training at Pfizer Central Research and the Yale University School of Medicine.
Dr. Miglarese’s deep expertise in laboratory science, translational oncology, and diagnostics will be invaluable as we advance and scale our minimally invasive, biomarker-based blood tests for the early detection of lung and gastric cancers. His guidance will support the integration of our innovations into clinical and laboratory practice, ensuring patients and physicians have access to faster, more accurate tools for early cancer detection.
Please join us in welcoming Dr. Miglarese to the Cizzle Bio team.
Detect Early. Save Lives.
